Rai Abhishek Kumar, Rathod Tushar Narayan, Bansal Dixit, Hadole Bhushan Sunil, Rahman Syed Hifzur, Kumar K G Geekesh, Prabhu Rudra Mangesh
Department of Orthopaedics Seth GS Medical College and KEM Hospital, Mumbai, India.
Department of Orthopaedics Government Medical College, Amritsar, India.
J Orthop. 2022 May 19;32:72-77. doi: 10.1016/j.jor.2022.05.010. eCollection 2022 Jul-Aug.
The study reports the efficacy of sequential instillations of intralesional percutaneous polidocanol in the treatment of skeletal ABC. The study also analyses the pain relief, recurrence, radiological outcome and complications after percutaneous sclerotherapy.
A total of 43 patients with ABC were managed by fluoroscopy assisted percutaneous intralesional sclerotherapy with 3% Injection Polidocanol under suitable anaesthesia. The pain relief was assessed by Visual Analog Scale (VAS) and the progressive healing of the lesion by Rastogi Classification. Patients were evaluated clinico-radiologically, pre-operatively and at monthly interval for the first three months and then at 6 months, one year and two years follow up.
The VAS score decreased significantly at six months follow up and was zero (No pain) at one year follow up. Out of 43 patients, 37 patients had Degree I (excellent) residual lesion and 6 patients had degree II (good) lesion at one year follow-up as per Rastogi classification. The lesions resolved completely by two-year follow-up with all 43 patients having Degree (excellent) I resolution.
Our study highlights the efficacy of percutaneous intralesional polidocanol in the treatment of ABC's. The procedure is safe, simple and effective with excellent outcome. Sclerotherapy is highly beneficial for deep lesions which are difficult to assess and for comorbid patients who are medically unfit for surgery. Our study strongly advocates the use of sclerotherapy as the first line treatment for ABC, considering its clinical and radiological efficacy.
本研究报告经皮病灶内注射聚多卡醇序贯治疗骨嗜酸性肉芽肿(ABC)的疗效。本研究还分析了经皮硬化治疗后的疼痛缓解情况、复发情况、影像学结果及并发症。
43例ABC患者在适当麻醉下,在透视引导下经皮病灶内注射3%聚多卡醇注射液进行硬化治疗。采用视觉模拟评分法(VAS)评估疼痛缓解情况,采用Rastogi分类法评估病变的逐渐愈合情况。对患者进行临床和影像学评估,术前及术后前三个月每月评估一次,然后在6个月、1年和2年随访时评估。
随访6个月时VAS评分显著降低,随访1年时为零(无疼痛)。根据Rastogi分类,43例患者中,37例在1年随访时有I度(优秀)残留病变,6例有II度(良好)病变。随访2年时病变完全消退,所有43例患者均达到I度(优秀)消退。
我们的研究突出了经皮病灶内注射聚多卡醇治疗ABC的疗效。该方法安全、简单、有效,效果极佳。硬化治疗对难以评估的深部病变以及因医学原因不宜手术的合并症患者非常有益。考虑到其临床和影像学疗效,我们的研究强烈主张将硬化治疗作为ABC的一线治疗方法。